|
Boston Scientific Targets Asthma
Daily Markets Leading medical devices player Boston Scientific Corporation (NYSE:BSX) presented long-term safety data from the Research in Severe Asthma (RISA) trial. The study revealed that patients with severe refractory asthma, when treated with Alair bronchial … |
View full post on asthma – Google News